^
Association details:
| Biomarker: | ALK S1206Y |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Zykadia (ceritinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
Published date:
07/05/2017
Excerpt:
The activity of ceritinib against nine additional ALK mutations conferring resistance to crizotinib was tested in Ba/F3 cells. Ceritinib potently inhibited the growth of those cells expressing the most common mutations, L1196M, G1269A and also S1206Y and I1171T, but not those with C1156Y, G1202R, 1151Tins, L1152R and F1174C mutations...
DOI:
10.2147/DDDT.S113500
